Colossal Biosciences Engineered Three Dire Wolf Pups

The company used ancient DNA and gene editing to produce the first living dire wolves in 12,500 years.

Updated on Oct. 10, 2026 in Biotech

Colossal Biosciences Engineered Three Dire Wolf Pups

Live Poll

Do you support using genetic engineering to bring extinct species back to Earth?

On October 1, 2024, Colossal Biosciences announced the birth of three genetically engineered dire wolf pups, named Romulus, Remus, and Khaleesi. These pups were carried to term by domestic dog surrogates in North Texas.

Why it matters

The project serves as a testbed for synthetic biology and CRISPR tools that Colossal aims to apply to broader conservation efforts and human healthcare technologies. This milestone marks the first time the company has successfully resurrected a species that went extinct 12,500 years ago.

Colossal Biosciences reconstructed the extinct genome by mapping ancient fossil DNA onto the modern gray wolf genome. Researchers then edited the cells of living gray wolves to generate the embryos, which were implanted into domestic surrogate mothers.

The players

Colossal Biosciences

A synthetic biology firm focused on de-extinction, utilizing CRISPR and genomic mapping to recreate extinct species with a $10.2 billion valuation.

Ben Lamm

The CEO and founder of Colossal Biosciences who directs the firm's strategic focus on conservation-based gene editing.

Astromech

A spin-off company created by Colossal Biosciences that achieved a $2 billion valuation in March 2026.

The details

The process relied on CRISPR, a technology used for precise gene editing, to introduce ancient genetic markers into current gray wolf cells. By creating these hybrids, the company successfully bridged the 12,500-year evolutionary gap since the species was last seen in nature. The pups demonstrate that the underlying genetic reconstruction methods are functional at a biological level.

March 2026: Astromech spin-off valued at $2 billion.
July 2026: Colossal announced a $200 million Series C round.
October 1, 2026: Ben Lamm spoke at the CNBC AI Forum.
2030s: Planned birth of a woolly mammoth.

The Tech Race

This achievement serves as a proof-of-concept milestone for Colossal's primary objective of woolly mammoth de-extinction. The company is positioning its synthetic biology platform against conventional conservation methods, aiming to deliver additional extinct species over the next two years.

This development is currently contained within the research sector and does not offer direct utility to the public. Future shifts in healthcare applications resulting from these CRISPR-based advancements will likely be measured by industry-level milestones rather than consumer product cycles.

The takeaway

The successful birth of these pups confirms that Colossal's genetic reconstruction platform has moved from digital mapping to biological reality. Observers should track the company's progress toward its 2030s timeline for the woolly mammoth birth as the next indicator of operational scale.